Two gene editing firms unveil cancer drug pacts as ASCO comes to a close – Boston Business Journal

Two gene editing firms unveil cancer drug pacts as ASCO comes to a close
Boston Business Journal
The research drew blowback from Intellia, which said that the claim about off-target effects lacked evidence and was based on a sample. In addition to Intellia and CRISPR Therapeutics, the other leading gene-editing firm is Cambridge-based Editas ...

and more »

More here:
Two gene editing firms unveil cancer drug pacts as ASCO comes to a close - Boston Business Journal

Related Posts

Comments are closed.